Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TKI963

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 6, 2003, Pages 817-829

  Bilder, Glenda ^a,h   Amin, Dilip ^a   Morgan, Lisa ^b   McVey, Matthew ^c   Needle, Saul ^c   Galczenski, Helen ^d   Leadley, Robert ^e   He, Wei ^a   Myers, Michael ^f   Spada, Alfred ^e   Luo, Yongyi ^a   Natajaran, Chandra ^a   Perrone, Mark ^g  

^a SANOFI   (France)

^b GUILFORD PHARMACEUTICALS INC   (United States)

^c GLAXOSMITHKLINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e PFIZER INC   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g MERRIMACK PHARMACEUTICALS   (United States)

^h Merrimack Pharmaceuticals ^*  (United States)

Author keywords

Atherosclerosis; Coronary disease; Intravascular ultrasound; Platelet derived growth factors; Smooth muscle cell

Indexed keywords

ACETYLSALICYLIC ACID; COLONY STIMULATING FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; JANUS KINASE; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; TICLOPIDINE; TKI 963; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHEMOTAXIS; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; CYTOTOXICITY; DRUG MECHANISM; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTRAVASCULAR ULTRASOUND; MALE; MINIMUM INHIBITORY CONCENTRATION; MITOGENESIS; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESTENOSIS; SWINE; VASCULAR SMOOTH MUSCLE;

EID: 12444292763     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200306000-00001     Document Type: Article

References (52)

1. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society of Cardiac Angiography and Interventions. Cathet Cardiovasc Intervent. 2000;49:19-22.
2. Van Domburg RT, Foley DP, de Jaegere PP, et al. Long term outcome after coronary stent implantation: a 10 year single center experience with 1000 patients. Heart. 1999;82(suppl 11):27-34.
3. Strawn LM, Shawver LK. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opinion on Investigational Drugs. 1998;7:553-73.
4. Walters DL, Harding SA, Palacios IF, et al. The use of mechanical devices as adjuncts to intracoronary stenting. Curr Opin Cardiol. 2001;16:300-5.
5. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med. 1998;339:1672-8.
6. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999;341:319-27.
7. Carter AJ, Laird JR, Farb A, et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24:1398-405.
8. Miller DD, Karim MA, Edwards WD, et al. Relationship of vascular thrombosis and inflammatory leukocyte infiltration to neointimal growth following porcine coronary artery stent placement. Atherosclerosis. 1996; 124:145-55.
9. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histologic and immunohistochemical analyses. Circulation. 1998;98:224-33.
10. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
11. Neville RF, Sidawy AN. Myointimal hyperplasia: basic science and clinical considerations. Semin Vasc Surg. 1998;11:142-8.
12. Bilder GE, Rojas CJ. Inhibitors of the platelet-derived growth factor receptor tyrosine kinase. Cardiovasc Rev. 1996;14:380-99.
13. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol. 2000;81:63-88.
14. Myllarniemi M, Frosen J, Calderon Ramirez LG, et al. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther. 1999;13:159-68.
15. Tanizawa S, Ueda M, van der Loos CM, et al. Expression of platelet-derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart. 1996;75:549-56.
16. Ueda M, Becker AE, Kasayuki N, et al. In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Am J Pathol. 1996; 149:831-43.
17. Brasen JH, Kivela A, Roser K, et al. Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arterioscler Thromb Vasc Biol. 2001;11:1720-6.
18. Golomb G, Fishbein I, Banai S, et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis. 1996;125:171-82.
19. Myllarniemi M, Calderon L, Lemstrom K, et al. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 1997;11:1119-26.
20. Bilder G, Wentz T, Leadley R, et al. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR 101511A. Circulation. 1999;99:3292-9.
21. Dolle RE, Dunn JA, Bobko M, et al. 5,7-Dimethoxy-3-(4-pyridinyl) quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 1994;37:2627-9.
22. Bilder GE, Krawiec JA, McVety K, et al. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol. 1991;260:C721-30.
23. Walsh BJ, Thorton SC, Penny R, et al. Microplate reader-based quantitation of collagens. Anal Biochem. 1992;203:187-90.
24. Myers MR, Setzer NN, Spada AP, et al. The synthesis and SAR of new 4-(n-alkyl-n-phynyl) amino-6, 7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl) amino-pyrazolo-(3,4-d) pyrimidines, inhibitors of CSF-1R tyrosine. Bioorg Med Chem Lett. 1997;7:421-4.
25. Saltzman A, Stone M, Franks C, et al. Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem Biophys Res Commun. 1998;246:627-33.
26. Park YW, Cummings RT, Wu L, et al. Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal Biochem. 1999;269:94-104.
27. Kashiwagi A, Verso MA, Andrews J, et al. In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest. 1983;72:1246-54.
28. Carpenter G, King L Jr, Cohen S. Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor. J Biol Chem. 1979;254:4884-91.
29. Myers MR, Spada AP, Persons PE, et al. Aventis Pharmaceuticals Products, assignee. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases. US patent 6159978. December 12, 2000.
30. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
31. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-316.
32. Schwartz SM, Reidy MA, O'Brien ERM. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost. 1995;74:541-51.
33. Clunn GF, Refson JS, Lymn JS, et al. Platelet-derived growth factor β-receptors can both promote and inhibit chemotaxis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17:2622-9.
34. Jiang B, Yamamura S, Nelson PR, et al. Differential effects of platelet-derived growth factor isotypes on human smooth muscle cell proliferation and migration are mediated by distinct signaling pathways. Surgery. 1996;120:427-32.
35. MacLeod DC, Strauss BH, de Jong M, et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994;23:59-65.
36. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 1994;75:650-8.
37. Nikkari ST, Jarvelainen HT, Wight TN, et al. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 1994; 144:1348-56.
38. Palmer BD, Smaill JB, Boyd M, et al. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998;41:5457-65.
39. Maguire MP, Sheets KR, McVety K, et al. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994;37:2129-37.
40. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998;17:5896-904.
41. Kovalenko M, Ronnstrand L, Heldin C-H, et al. Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 1997;36:6260-9.
42. Banai S, Wolf Y, Golomb G, et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 1998;97:960-9.
43. Antoniucci D, Valenti R, Moschi G, et al. Stenting for in-stent restenosis. Cathet Cardiovasc Intervent. 2000;49:376-81.
44. Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol. 2000;35:1569-76.
45. De Feyter PJ, Ruygrok PN, Mills P. Some thoughts on the present and future of coronary artery stenting. Heart. 1996;75:546-8.
46. McKenna CJ, Burke SE, Opgenorth TJ, et al. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation. 1998;97:2551-6.
47. Hong, MK, Kent KM, Mehran R, et al. Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Circulation. 1997;95:449-54.
48. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998;32:780-6.
49. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-95.
50. Buchwald AB, Unterberg C, Nebendahl K, et al. Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation. 1992;86:531-7.
51. Rodgers GP, Minor ST, Robinson K, et al. The coronary artery response to implantation of a balloon-expandable flexible stent in the aspirin- and non-aspirin-treated swine model. Am Heart J. 1991;122:640-7.
52. Churchill DA, Siegel CO, Minor ST, et al. Enalapril in the prevention of restenosis following intracoronary intervention in a swine model. Coron Artery Dis. 1993;4:461-67.